Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
Public ClinicalTrials.gov record NCT05074810. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Sotorasib With or Without Defactinib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)
Study identification
- NCT ID
- NCT05074810
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Verastem, Inc.
- Industry
- Enrollment
- 153 participants
Conditions and interventions
Interventions
- avutometinib and sotorasib Drug
- avutometinib and sotorasib and defactinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 11, 2022
- Primary completion
- May 31, 2026
- Completion
- Mar 31, 2027
- Last update posted
- Jan 11, 2026
2022 – 2027
United States locations
- U.S. sites
- 20
- U.S. states
- 13
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Rocky Mountain Cancer Center, LLP | Boulder | Colorado | 80303 | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | — |
| MedStar Washington Hospital Center, MedStar Georgetown Cancer Institute, | Washington D.C. | District of Columbia | 20010 | — |
| Illinois Cancer Specialists | Arlington Heights | Illinois | 60005 | — |
| Maryland Oncology & Hematology, P.A. | Rockville | Maryland | 20850 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Minnesota Oncology Hematology, P.A | Woodbury | Minnesota | 55125 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Cleveland Clinic Taussig Cancer Center | Cleveland | Ohio | 44195 | — |
| Ohio State University Brain and Spine Hospital | Columbus | Ohio | 43210 | — |
| Consultants in Medical Oncology & Hematology | Broomall | Pennsylvania | 19008 | — |
| Alliance Cancer Specialists, | Horsham | Pennsylvania | 19044 | — |
| Texas Oncology | Austin | Texas | 78731 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
| Texas Oncology - Fort Worth Cancer Center | Fort Worth | Texas | 76104 | — |
| Texas Oncology | Longview | Texas | 75601 | — |
| Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care | Blacksburg | Virginia | 24060 | — |
| Virginia Cancer Specialists, PC | Fairfax | Virginia | 22031 | — |
| Northwest Cancer Specialists | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05074810, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 11, 2026 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05074810 live on ClinicalTrials.gov.